Long-term Efficacy and Safety of Pasireotide in Patients With Acromegaly: 14 Years of Single-Center Real-World Experience
Authors:
Open Access
- 26 June 2023
- journal article
- research article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 108 (12) , e1571-e1579
Abstract
Context Acromegaly is a rare, chronic, debilitating disorder caused by prolonged hypersecretion of growth hormone (GH) and overproduction of insulin-like growth factor I (IGF-I). Medical therapies, including the somatostatin receptor ligand (SRL) pasireotide, are frequently used to restore biochemical control. Objective As patients often receive therapy over prolonged periods, long-term data from real-life settings are needed. Methods A retrospective analysis was performed using a prospectively maintained database of all patients with acromegaly from our primary care center who were enrolled in clinical studies with pasireotide (first visit November 2008). The main outcome measures were safety and biochemical control (age-adjusted IGF-I ≤ upper limit of normal). Results Patients (n = 50) entered 4 parental studies and 30 continued in the rollover; at data cutoff (June 2022), 27 were still receiving pasireotide. Overall, median (range) exposure was 58 (3-137) months. Normal IGF-I was achieved in 54%, and acromegaly symptoms and quality of life were improved with treatment. No predictors of pasireotide response were identified; however, controlled patients had smaller tumors and lower GH at baseline. Tumor volume reduction occurred in 63% of evaluable patients (n = 10/16). Most patients presented hyperglycemic events, including 63.2% of patients with normal glucose before treatment. Older patients and those with higher IGF-I, glucose, and HbA1c at baseline had higher glucose and HbA1c during pasireotide treatment. Conclusion Pasireotide provided clinical benefit and was well tolerated for more than 11 years of treatment in acromegaly patients, most of whom were resistant to first-generation SRLs.Keywords
Funding Information
- Novartis Pharma
- Recordati
- Recordati
- Mudskipper Business Ltd
This publication has 31 references indexed in Scilit:
- Pasireotide in Acromegaly: A ReviewDrugs, 2015
- Acromegaly: An Endocrine Society Clinical Practice GuidelineThe Journal of Clinical Endocrinology & Metabolism, 2014
- Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trialThe Lancet Diabetes & Endocrinology, 2014
- Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III studyPituitary, 2014
- Could different treatment approaches in acromegaly influence life expectancy? A comparative study between Bulgaria and Campania (Italy)European Journal of Endocrinology, 2014
- Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority StudyThe Journal of Clinical Endocrinology & Metabolism, 2014
- Expert consensus document: A consensus on the medical treatment of acromegalyNature Reviews Endocrinology, 2014
- Effects of subcutaneous pasireotide on cardiac repolarization in healthy volunteers: A single‐center, phase I, randomized, four‐way crossover studyThe Journal of Clinical Pharmacology, 2013
- Hyperglycemia Associated With Pasireotide: Results From a Mechanistic Study in Healthy VolunteersThe Journal of Clinical Endocrinology & Metabolism, 2013
- Quantitative analysis of somatostatin receptor subtypes (1–5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAREuropean Journal of Endocrinology, 2008